TY - JOUR
T1 - Recent developments in relaxin mimetics as therapeutics for cardiovascular diseases
AU - Leo, Chen Huei
AU - Jelinic, Maria
AU - Ng, Hooi Hooi
AU - Parry, Laura J.
AU - Tare, Marianne
PY - 2019/4
Y1 - 2019/4
N2 - Cardiovascular disease is the most common cause of mortality worldwide, accounting for almost 50% of all deaths globally. Vascular endothelial dysfunction and fibrosis are critical in the pathophysiology of cardiovascular disease. Relaxin, an insulin-like peptide, is known to have beneficial actions in the cardiovascular system through its vasoprotective and anti-fibrotic effects. However, relaxin has several limitations of peptide-based drugs such as poor oral bioavailability, laborious, and expensive to synthesize. This review will focus on recent developments in relaxin mimetics, their pharmacology, associated signalling mechanisms, and their therapeutic potential for the management and treatment of cardiovascular disease.
AB - Cardiovascular disease is the most common cause of mortality worldwide, accounting for almost 50% of all deaths globally. Vascular endothelial dysfunction and fibrosis are critical in the pathophysiology of cardiovascular disease. Relaxin, an insulin-like peptide, is known to have beneficial actions in the cardiovascular system through its vasoprotective and anti-fibrotic effects. However, relaxin has several limitations of peptide-based drugs such as poor oral bioavailability, laborious, and expensive to synthesize. This review will focus on recent developments in relaxin mimetics, their pharmacology, associated signalling mechanisms, and their therapeutic potential for the management and treatment of cardiovascular disease.
UR - http://www.scopus.com/inward/record.url?scp=85064837005&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2019.04.001
DO - 10.1016/j.coph.2019.04.001
M3 - Article
C2 - 31048209
AN - SCOPUS:85064837005
SN - 1471-4892
VL - 45
SP - 42
EP - 48
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
ER -
